Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The company also reported significant progress toward its internally defined Sustainable Development Goals
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The combination also outperformed chemotherapy on another important secondary endpoint
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Subscribe To Our Newsletter & Stay Updated
